Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program... Show more
Humana's quarterly earnings are a closely watched barometer for the broader Medicare Advantage (MA) industry, given the company's scale in government-sponsored health coverage. The third quarter has been a pivotal checkpoint for investors assessing whether Humana can absorb the Star Ratings headwind for bonus year 2026, which has pressured margins and pushed adjusted results into a loss. Strong Medicare membership growth and disciplined cost management have supported revenue, but medical cost trends and benefit ratio performance remain central to the profit story. The report also offered a progress update on Humana's multiyear margin recovery plan, making the guidance revision and commentary on 2027 positioning especially meaningful for both current shareholders and those evaluating the managed care sector.
Humana posted a third quarter 2026 adjusted loss of $0.70 per share, a meaningful improvement versus the consensus estimate of roughly a $1.00 loss, but a sharp reversal from adjusted earnings of $3.24 per share in the prior-year period. On a GAAP basis, diluted EPS was $1.33, down from $1.62 a year earlier and boosted by a noncash gain related to restructuring its primary care joint ventures.
Total revenue rose about 26% year over year to $41.16 billion, ahead of consensus estimates near $40.9 billion. Premiums increased roughly 26% to $38.7 billion, while services revenues climbed about 33%. Total medical membership reached 18.04 million, up from 14.99 million a year ago, with individual Medicare Advantage membership growing to 6.46 million. The insurance segment benefit ratio improved to 93.7%, better than management's "slightly above 94%" guidance.
Management raised full year 2026 adjusted EPS guidance to at least $9.50, from at least $9.00, while full year 2026 GAAP EPS guidance was raised to at least $15.09 from $6.52. Full year revenue guidance of at least $160 billion was reaffirmed, slightly below some analyst estimates.
Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics, making it easier to identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Whether you are tracking a single name like Humana or scanning entire sectors, the screener can help streamline your research workflow and surface actionable ideas.
Sentiment heading into the report was cautious, with investors focused on whether the Star Ratings headwind would deepen the expected quarterly loss. Humana's narrower-than-expected loss, revenue beat, and raised full year adjusted EPS guidance were received constructively, though the stock's initial move was mixed, with shares trading modestly higher in early activity after the announcement. Investors appeared to weigh the improved near-term execution against a full year revenue outlook that remained slightly below some consensus figures. Commentary around a top-quartile Star Ratings result for bonus year 2028 and strong early performance in the annual election period for 2027 provided additional support, positioning the report as a broadly encouraging update despite the headline adjusted loss.
Looking ahead, investors will focus on Humana's ability to translate its operational momentum into margin recovery. Management signaled that cost trends are tracking in line to better than expectations and reaffirmed its goal of restoring individual Medicare Advantage margins toward the 3% range by 2028. The strong Star Ratings result for bonus year 2028 is expected to create a one-time financial tailwind, a portion of which management anticipates returning to shareholders.
Several catalysts remain on the horizon. The company plans an investor update in December and expects to close the divestment of its minority interest in Gentiva, generating roughly $900 million in pretax proceeds. The new BlackRock joint venture is also expected to reduce the GAAP debt-to-capital ratio in the fourth quarter. At the same time, investors should monitor medical cost trends and prescription drug (Part D) cost pressures heading into 2027, where management has pointed to higher trends driven by specialty pharmaceuticals. How membership retention and new sales ultimately land during the annual election period will be another key factor shaping next year's margin trajectory.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a company offers health insurance coverage and related services
Industry ManagedHealthCare